During the corresponding time, Intellia Therapeutics Inc saw a revenue deteriorated by -46.23 % year on year, sequentially revenue fell by -49.1 %. While revenue at the Intellia Therapeutics Inc 's corporate clients
Intellia Therapeutics Inc's Comment on Sales, Marketing and Customers
The company operates in the markets for in vivo genome editing products and ex vivo engineered cell therapies utilizing CRISPR genome editing technology. Its potential customers and market segments include physicians, patients, hospitals, third-party payors, and other members of the medical community. The company collaborates with entities such as Regeneron Pharmaceuticals, Inc. in the development and potential commercialization of its products.
In the fast-paced world of biotechnology, the importance of protecting investor interests cannot be overstated. As the landscape shifts with breakthrough research and corporate developments, the cautionary tales of missteps and missed opportunities proliferate. In this regard, Rosen Law Firm, a respected global investor rights law firm, is sounding the alarm for those who have invested in Intellia Therapeutics, Inc. (NASDAQ: NTLA). The firm is urging any investors who purchased securities in the company between July 30, 2024, and January 8, 2025, to secure counsel before the crucial April 14, 2024, lead plaintiff deadline in a securities class action lawsuit.Why the rush The backdrop of this legal initiativ...
In the world of investment, legal challenges are often indicative of deeper systemic issues within corporations. Recently, Bragar Eagel and Squire, P.C. a heavyweight in shareholder rights legal action, announced class action lawsuits against several big-name corporations FMC Corporation, Elastic N.V. Intellia Therapeutics, and Merck and Co. Inc. This surge of legal activity could have far-reaching implications for these companies and their stakeholders. Unpacking the Lawsuits For investors, understanding the nature of these lawsuits is crucial. Bragar Eagel and Squire emphasized that these actions have been launched on behalf of shareholders, signaling possible missteps or omissions by the companies, potent...
Hereditary angioedema (HAE) is a genetic disorder characterized by recurrent episodes of severe swelling in various body parts, including the face, extremities, gastrointestinal tract, and airway. The root cause of HAE is a deficiency or dysfunction of C1 esterase inhibitor (C1-INH), a protein that regulates various pathways in the immune system and coagulation. Traditional therapeutic approaches have managed HAE symptoms rather than addressing the underlying genetic defect. However, recent advancements in gene-editing technology, particularly CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), offer promising avenues for curative treatment. Intellia Therapeutics, a leading clinical-stage gen...
Intellia Therapeutics Gears Up for ACAAI Presentation: Promising Data for NTLA-2002 in Hereditary Angioedema Amid Mixed Financial Performance Intellia Therapeutics, Inc. (NASDAQ: NTLA), a pioneering entity in the field of clinical-stage gene editing, has announced a significant milestone in its ongoing efforts to develop groundbreaking therapies for rare diseases. On September 12, 2024, the company revealed plans to present data from its Phase 2 study of NTLA-2002 at the 2024 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting, scheduled to take place from October 24 to 28 in Boston, Massachusetts.NTLA-2002 represents a cutting-edge approach to addressing hereditary angioedem...
First-Ever Re-Dosing With Investigational In Vivo CRISPR Therapy: Insights and Implications Intellia Therapeutics has recently presented groundbreaking clinical data on the safety and pharmacodynamics of redosing patients with their investigational in vivo CRISPR gene editing therapy. This therapy, which leverages lipid nanoparticle (LNP) technology for systemic delivery, marks a significant milestone in genetic medicine. Concurrently, Intellia s financial reports show a complex landscape, with a year-over-year revenue decline of 3.11% but a sequential quarter increase of 7.84%. This article aims to synthesize these clinical and financial developments, providing a comprehensive analysis of their implication...
Hereditary angioedema (HAE) is a rare genetic condition characterized by recurrent episodes of potentially life-threatening swelling attacks. Current treatment options for HAE are limited and often inadequate, highlighting the need for innovative approaches to address this debilitating disease. In recent years, gene editing technologies such as CRISPR have emerged as promising tools for targeted therapy development. This article explores the latest updates from Intellia Therapeutics Phase 1/2 study of NTLA-2002, an investigational in vivo CRISPR-based gene editing therapy for HAE, and discusses its potential implications for the future of HAE treatment.Background:HAE is caused by mutations in the C1 inhibit...
Intellia Therapeutics, a renowned clinical-stage gene editing company, has recently commenced the global pivotal, Phase 3 MAGNITUDE trial of their investigational therapy, NTLA-2001. This single-dose, in vivo CRISPR-based treatment aims to inactivate the TTR gene, thereby preventing the production of TTR protein in patients with transthyretin (ATTR) amyloidosis with cardiomyopathy. This article presents an overview of the significance and potential impact of this groundbreaking study.Phase 3 MAGNITUDE Trial Details:The Phase 3 MAGNITUDE trial is designed to evaluate the efficacy and safety of NTLA-2001 in patients suffering from ATTR amyloidosis with cardiomyopathy. By targeting the underlying cause of the d...
Intellia Therapeutics and ReCode Therapeutics Collaborate to Develop Groundbreaking Gene Editing Therapies for Cystic FibrosisIntellia Therapeutics, a prominent gene editing company, and ReCode Therapeutics, a genetic medicines company, have announced a strategic collaboration to develop innovative genomic medicines for the treatment of cystic fibrosis (CF). This partnership aims to leverage their expertise in CRISPR-based therapies and tissue-specific delivery to address the underlying cause of CF and potentially revolutionize its treatment.CF is a genetic disease that arises from mutations in the CFTR gene, resulting in the buildup of thick mucus in vital organs such as the lungs and digestive system. This...
Intellia Therapeutics Inc’s Comment on Sales, Marketing and Customers
The company operates in the markets for in vivo genome editing products and ex vivo engineered cell therapies utilizing CRISPR genome editing technology. Its potential customers and market segments include physicians, patients, hospitals, third-party payors, and other members of the medical community. The company collaborates with entities such as Regeneron Pharmaceuticals, Inc. in the development and potential commercialization of its products.
Sources:
Intellia Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Intellia Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Intellia Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
296.47 %